A warm welcome is extended to EVI's new Project Manager, Soazic Gardais, who commenced duties on 27 June 2016.
The following products are now available on the The National Institute for Biological Standards and Control (NIBSC) website:
Influenza Virus Infectious NIBRG-306 ( Influenza Reagent )
23-06-2016 01:00 AM BST
As of 15 June 2016 EVI is domiciled at:
European Vaccine Initiative UniversitätsKlinikum Heidelberg Vossstrasse 2, Geb. 4040 69115 Heidelberg, Germany
European public and private organisations are collaborating in VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2) to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods.
EVI is proud to announce that the 2016 Christophe Mérieux award has been given to Francine Ntoumi.
Each year, the Institut de France’s Christophe and Rodolphe Mérieux Foundationawards a scientific ’Grand Prize’ entitled the ’Christophe Mérieux Prize’ to support research on infectious diseases in developing countries. The Prize exclusively rewards research teams working permanently in these countries.
EVI is pleased to welcome Samuel McConkey on the Board as representative of the Royal College of Surgeons in Ireland (RCSI). His predecessor Ruairí Brugha will be remembered for his valuable input and commitment for which EVI is most grateful.Samuel McConkey knows EVI very well as he served for several years as an independent expert on the EVI Scientific Advisory Committee (SAC).
A special issue of the journal Vaccine, guest-edited by WHO and published today, focuses on the research and development (R&D) pipeline of vaccines against 25 pathogens for which no licensed vaccines currently exists but for which there is high public health importance, as identified by the WHO Product Development for Vaccines Advisory Committee (PDVAC).
... Rapid Progress on New Technologies for Neglected Diseases
GHIT’s projects have progressed quickly in three years thanks to just such a scale-up in projects run by global collaborations. In fact, just in the last year, four progressed to clinical trials:
On 21 January French Clinical Research Infrastructure Network (F-CRIN) organised the first full day meeting (programme) at Institut Pasteur with the health industry. The meeting was a forum for a valuable mutual exchange of expertise with F-CRIN's clinical research.
Relevant video and presentations
The following publication relating to the EVI coordinated and EC funded EMVDA project: Immunogenicity of diamorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice, was recently published in Vaccine
The abstract is also available on this web site under publications.